1049695-95-5 Usage
Description
4-Methoxy-alpha-methyl-N-(phenylmethyl)benzeneethanamine hydrochloride is a sympathomimetic amine drug that functions as a central nervous system stimulant. It is recognized for its ability to elevate neurotransmitter levels, particularly dopamine and norepinephrine, which results in enhanced cognitive functions such as focus, attention, and alertness.
Uses
Used in Pharmaceutical Industry:
4-Methoxy-alpha-methyl-N-(phenylmethyl)benzeneethanamine hydrochloride is used as a therapeutic agent for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy due to its stimulant properties that improve cognitive performance and reduce excessive sleepiness.
Used in Medical Applications:
In the medical field, 4-Methoxy-alpha-methyl-N-(phenylmethyl)benzeneethanamine hydrochloride is utilized as a CNS stimulant to address conditions characterized by impaired attention and alertness, supporting patients in managing their symptoms more effectively.
Check Digit Verification of cas no
The CAS Registry Mumber 1049695-95-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,4,9,6,9 and 5 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1049695-95:
(9*1)+(8*0)+(7*4)+(6*9)+(5*6)+(4*9)+(3*5)+(2*9)+(1*5)=195
195 % 10 = 5
So 1049695-95-5 is a valid CAS Registry Number.
1049695-95-5Relevant articles and documents
PROCESS FOR THE SYNTHESIS OF ARFORMOTEROL
-
Page/Page column 31-32, (2009/12/28)
The present invention provides a process for preparing a compound of formula (Vl) or a salt thereof, the process comprising: (i) reacting 4-methoxyphenyl acetone with an amine of formula (VIII) under conditions of reductive amination to produce a compound of formula (II) or a salt thereof, wherein there is no isolation of an imine intermediate formed during the reductive amination; (ii) condensing the compound (II) or the acid addition salt thereof with an α-haloketone of formula (III) to produce the compound of formula (IV); (iii) reducing the compound (IV) to a compound of formula (V); and (iv) reducing the compound (V) to the compound of formula (Vl), wherein the reduction is carried out in the presence of either (1 ) a hydrogen donating compound in the presence of a hydrogen transfer catalyst; or (2) ammonium formate using a hydrogenation catalyst, wherein: R1 and R2 are independently optionally substituted arylalkyl, and Hal is selected from chloro or bromo.
